Lite Strategy (LITS) EBT Margin (2016 - 2023)
Lite Strategy (LITS) posted EBT Margin of 86.34% for Q3 2023, up 112.56% on a QoQ basis from 687.51% in Q2 2023, and up 28953.0% year-over-year from N/an in Q3 2022.
Powered by 
Analysis
Lite Strategy (LITS) EBT Margin (2016 - 2023) Analysis & Trends
Lite Strategy has reported EBT Margin for 8 years, with the latest figure at 86.34% in Q3 2023.
- On a quarterly basis, EBT Margin rose 28953.0% year-over-year to 86.34% in Q3 2023; TTM through Jun 2024 was 27.29%, a 9575.0% increase from a year earlier, with the FY2024 full-year figure at 27.29%, up 9575.0% from the prior year.
- EBT Margin was 86.34% for Q3 2023 at Lite Strategy, up from 687.51% in the prior quarter.
- The five-year high for EBT Margin was 86.34% in Q3 2023, with the low at 1169.74% in Q4 2019.
- Average EBT Margin over 5 years is 402.89%, with a median of 207.42% recorded in 2021.
- The sharpest annual moves came in 2019 and 2020: EBT Margin slumped 61279 bps in 2019, then surged 104759 bps in 2020.
- Over 5 years, EBT Margin stood at 1169.74% in 2019, then soared by 89 bps to 123.93% in 2020, then slipped by 20 bps to 148.87% in 2021, then surged by 120 bps to 29.85% in 2022, then soared by 189 bps to 86.34% in 2023.
- The last three EBT Margin figures came in at 86.34% (Q3 2023), 687.51% (Q2 2023), and 261.86% (Q1 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 86.34% |
| Jun 30, 2023 | -687.51% |
| Mar 31, 2023 | -261.86% |
| Dec 31, 2022 | 29.85% |
| Sep 30, 2022 | -203.20% |
| Jun 30, 2022 | -140.09% |
| Mar 31, 2022 | -221.77% |
| Dec 31, 2021 | -148.87% |
| Sep 30, 2021 | -259.08% |
| Jun 30, 2021 | -207.42% |
| Mar 31, 2021 | -201.47% |
| Dec 31, 2020 | -123.93% |
| Sep 30, 2020 | -188.49% |
| Jun 30, 2020 | 46.26% |
| Mar 31, 2020 | -969.53% |
| Dec 31, 2019 | -1,169.74% |
| Sep 30, 2019 | -1,059.90% |
| Jun 30, 2019 | -1,001.33% |
| Mar 31, 2019 | -973.10% |
| Dec 31, 2018 | -556.95% |